sponsored
PatientsVille.com Logo

PatientsVille

Esomeprazole Medical Research Studies

Up-to-date List of Esomeprazole Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Esomeprazole Medical Research Studies

Rank Status Study
1 Unknown  A Double Blind Study Comparing Two Doses of IV Esomeprazole After Successful Endoscopic Therapy
Condition: Upper Gastrointestinal Bleeding
Interventions: Drug: Esomeprazole;   Drug: Esomeprazole
Outcome Measure: Two different doses intravenous proton pump inhibitors in patients with peptic ulcer bleeding after successful endoscopic therapy- a prospective randomized comparative trial.
2 Unknown  Effect of Esomeprazole 40 mg.Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients With GERD
Condition: Gastroesophageal Reflux Disease
Interventions: Drug: Esomeprazole;   Drug: Esomeprazole
Outcome Measure: The Effect of Esomeprazole 40 mg. Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients w/ GERD.
3 Not yet recruiting Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients
Condition: Stress Ulcer Prophylaxis
Interventions: Drug: Esomeprazole;   Drug: Cimetidine
Outcome Measures: The effectiveness of Esomeprazole versus cimetidine for the prevention of upper GI bleedings;   The proportion of patients with any overt upper GI bleeding
4 Recruiting High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer
Condition: Bleeding Peptic Ulcer
Interventions: Drug: Esomeprazole Na;   Drug: Cimetidine;   Drug: Esomeprazole Mg
Outcome Measures: The rate of clinically significant rebleeding of continuous i.v. infusion;   The rate of clinically significant rebleeding;   The rate of patients had endoscopic re-treatment due to rebleeding;   The rate of patients who had surgery due to rebleeding;   The number of blood units transfused;   The number of patients with AE during the continuous I.v. infusion;   The number of patients with AE of open oral treatment with Esomeprazole Mg 40 mg;   Mean values of S-creatinine, S-ALP, S-AST, S-ALT, B-Bil, Hb, WBCand B-platelets
5 Not yet recruiting Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia
Condition: Dyspepsia
Interventions: Drug: Rebamipide;   Drug: Placebo (for Esomeprazole);   Drug: Esomeprazole
Outcome Measures: Dyspepsia symptoms;   quality of life
6 Unknown  Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia
Conditions: Aspirin;   Dyspepsia
Interventions: Drug: Esomeprazole;   Drug: Famotidine
Outcome Measures: Treatment success : The HKDI is less than 16. Treatment was considered to have failed if a patient had taken medication for dyspepsia (other than antacids) during the study period;   Treatment success: no significant dyspepsia defined by the Global Dyspepsia Score
7 Recruiting Comparison of the Gastric Acid Suppressive Effects of Esomeprazole and Generic Omeprazole
Condition: Gastric Acid
Interventions: Drug: Esomeprazole first;   Drug: Generic omeprazole first
Outcome Measures: Median intragastric pH and percentage of time that intragastric pH is above 4;   Nocturnal acid breakthrough, defined as at least 60 continuous minutes of intragastric pH below 4 occurring between 10pm and 6 am and adverse events
8 Recruiting The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding and the Selection Criteria for Second-look Endoscopy for Patients With Bleeding Peptic Ulcers
Condition: Peptic Ulcer Bleeding
Intervention: Drug: Esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)
Outcome Measures: recurrent bleeding;   the length of hospitalization;   the amount of blood transfusion;   major events such as surgery or transarterial embolization;   the fading rate of major stigmata of recent hemorrhage;   mortality
9 Unknown  Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC
Condition: Gastroesophageal Reflux Disease
Interventions: Drug: Nexium®;   Drug: Esomeprazol (40mg) + Sdium Bicarbonate (721mg)
Outcome Measure: Efficacy
10 Not yet recruiting A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of RO5424802 in Healthy Volunteers.
Condition: Healthy Volunteer
Interventions: Drug: RO5424802;   Other: Hight fat and calorie meal;   Other: Standard meal;   Drug: Esomeprazole
Outcome Measures: Plasma area under the concentration-time curve (AUC) of RO5424802;   Incidence of adverse events;   Plasma AUC of major metabolite after RO5424802 administration
11 Recruiting Rate of Complete Symptom Relief, Prevention of Symptom Relapse and Maintenance: Grades A and B Esophagitis of Esomeprazole Therapy
Condition: Erosive Esophagitis
Intervention: Drug: Esomeprazole 40 mg
Outcome Measures: The Rates of Complete Symptom Relief;   The Rate of Symptom Relapse
12 Unknown  Comparison of Nexium VS. Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.
Conditions: Gastroesophageal Reflux Disease (GERD);   Heartburn;   Indigestion
Interventions: Drug: Secretol;   Drug: Nexium
Outcome Measure: Primary objective is to evaluate the relationship between healing and study drug allotment.
13 Unknown  Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection
Conditions: Helicobacter Pylori Infection;   Chronic Gastritis
Interventions: Drug: Esomeprazole;   Drug: moxifloxacin;   Drug: amoxicillin
Outcome Measures: Efficacy of a combination of Esomeprazole (E), moxifloxacin (M) and amoxicillin (A) for third line therapy of H. pylori infection.;   Comparison of EMA 7 days versus EMA 14 days. Hypothesis: superiority of EMA 14 days 4 weeks after end of eradication therapy;   Tolerability,safety, post treatment resistance, influence of host genetics (CYP status) and pathogenicity factors of H. pylori on treatment success.
14 Unknown  Esomeprazole Treatment for Patients With Lymphocytic Gastritis
Condition: Lymphocytic Gastritis
Intervention: Drug: Esomeprazole
Outcome Measures: The primary objective is to assess the healing rate of;   patients with lymphocytic gastritis irrespective of H. pylori status after treatment;   with Esomeprazole 20 mg twice daily for 2 weeks.;   Secondary objective of the study are to evaluate the grade and activity of gastritis before and after;   treatment according to updated Sydney classification, to assess the clinical GI symptoms at baseline and after 3 months;   and to evaluate influence of the H. pylori-Status
15 Recruiting Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Conditions: Solid Tumors;   Lymphoma
Interventions: Drug: alisertib;   Drug: Esomeprazole;   Drug: rifampin
Outcome Measures: alisertib PK parameters (AUC and Cmax) in the presence (Cycle 2 Day 8) versus absence (Cycle 1 Day 1) of Esomeprazole;   alisertib PK parameters (AUC and Cmax) in the presence (Cycle 2 Day 8) versus absence (Cycle 1 Day 1) of rifampin;   Change in QTc following single and multiple dose administration of alisertib;   alisertib steady-state PK parameters (AUC and Cmax);   Number of adverse events;   Changes in ECG intervals following single and multiple dose administration of alisertib
16 Recruiting A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
Condition: Juvenile Idiopathic Arthritis (JIA)
Interventions: Drug: VIMOVO 250/20;   Drug: VIMOVO 375/20;   Drug: VIMOVO 500/20
Outcome Measures: Incidence of severity of AEs and SAEs.;   Change in serum iron/total iron binding capacity (serum iron/TIBC), Vitamin B12, and magnesium.;   Change from baseline in vital signs, physical examination results and clinical laboratory tests.;   Pharmacokinetic (PK) in terms of characteristics of VIMOVO (naproxen / Esomeprazole).
17 Unknown  Evaluation of Esomeprazole in Treating Gastro-Esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy
Condition: Gastro-Esophageal Reflux
Intervention: Drug: Esomeprazole (Nexium)
Outcome Measure:
18 Unknown  Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer
Condition: Peptic Ulcer
Intervention: Drug: Esomeprazole
Outcome Measures: percentage of time intragstric pH > 6 and > 4;   Median intragastric pH;   time to attain intragastric pH 4 & 6
19 Unknown  Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
Condition: Gastroesophageal Reflux Disease
Interventions: Drug: 10 mg ilaprazole;   Drug: 15 mg ilaprazole;   Drug: 40 mg Esomeprazole
Outcome Measures: the proportion of patients with healed esophagitis at week 8;   the proportion of patients healed at week 4;   resolution of clinical symptoms
20 Unknown  The Effect of Nexium on Transmucosal Esophageal Leak
Conditions: Reflux;   Esophagitis;   Barrett's Esophagus
Intervention: Drug: Esomeprazole (Nexium) 40 mg/day
Outcome Measures: Urine sucrose level falls below 90 mg after 8 weeks of therapy;   Reduction of patient symptoms consistent with GERD

These studies may lead to new treatments and are adding insight into Esomeprazole etiology and treatment.

A major focus of Esomeprazole research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Esomeprazole